BACKGROUND: Comparing international estimates of survival can be a useful way of highlighting differences in life expectancy between cystic fibrosis (CF) populations. In this study, we compared survival in two CF populations. METHODS: The current lifetable method takes age-specific mortality rates observed in a given year and applies them to a hypothetical population assuming those rates will remain the same in the future. This was used to compare median predicted survival in the United States (US) and the Republic of Ireland (RoI) (1986-2008). Median age at death among decedents was also examined. RESULTS: In both countries, median age at death was lower than median predicted survival. Successive increases in annual median predicted survival were not observed; rather an overall improvement was discerned over time. In the RoI, where absolute numbers of deaths were small, year-on-year fluctuations in age-specific mortality rates resulted in wide-ranging annual median predicted survival estimates. CONCLUSION: Median age at death is not a good measure of CF survival. Though median predicted survival improved in each country over the study period, between-country comparison at a given time point may be misleading for rare disorders like CF. Longitudinal outcomes must be examined. Copyright Â
BACKGROUND: Comparing international estimates of survival can be a useful way of highlighting differences in life expectancy between cystic fibrosis (CF) populations. In this study, we compared survival in two CF populations. METHODS: The current lifetable method takes age-specific mortality rates observed in a given year and applies them to a hypothetical population assuming those rates will remain the same in the future. This was used to compare median predicted survival in the United States (US) and the Republic of Ireland (RoI) (1986-2008). Median age at death among decedents was also examined. RESULTS: In both countries, median age at death was lower than median predicted survival. Successive increases in annual median predicted survival were not observed; rather an overall improvement was discerned over time. In the RoI, where absolute numbers of deaths were small, year-on-year fluctuations in age-specific mortality rates resulted in wide-ranging annual median predicted survival estimates. CONCLUSION: Median age at death is not a good measure of CF survival. Though median predicted survival improved in each country over the study period, between-country comparison at a given time point may be misleading for rare disorders like CF. Longitudinal outcomes must be examined. Copyright Â
Authors: Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton Journal: Thorax Date: 2014-09-25 Impact factor: 9.139
Authors: Sinead McEvoy; Lisa Lavelle; Aoife Kilcoyne; Colin McCarthy; Pim A deJong; Martine Loeve; Harm A W M Tiddens; Edward McKone; Charles G Gallagher; Jonathan D Dodd Journal: Eur Radiol Date: 2012-07-20 Impact factor: 5.315
Authors: Jenna Sykes; Sanja Stanojevic; Christopher H Goss; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Anne L Stephenson Journal: J Clin Epidemiol Date: 2015-10-03 Impact factor: 6.437
Authors: Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss Journal: Ann Intern Med Date: 2017-03-14 Impact factor: 25.391
Authors: Abaigeal D Jackson; Leslie Daly; Andrew L Jackson; Cecily Kelleher; Bruce C Marshall; Hebe B Quinton; Godfrey Fletcher; Mary Harrington; Shijun Zhou; Edward F McKone; Charles Gallagher; Linda Foley; Patricia Fitzpatrick Journal: Thorax Date: 2011-06-08 Impact factor: 9.139